---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000193"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:06:31.936395+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arbutus reports ~$123M cash, plans imdusiran Phase 2b in H1 2025; reduces burn to $47-50M

## Summary
- Cash, equivalents & investments ~$123M as of Dec 31, 2024; 2024 net cash burn ~$65M; 2025 burn expected $47-50M.
- Plans placebo-controlled Phase 2b trial of imdusiran + interferon + NA in HBeAg-negative cHBV with HBsAg ≤1000 IU/mL in H1 2025; target N=170.
- IM-PROVE I Phase 2a showed 50% functional cure (3/6) in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; 25% overall.
- AB-101 oral PD-L1 Phase 1a/1b Part 3 (28-day repeat doses) data expected in H1 2025; next steps determined after.
- LNP litigation: claim construction hearing for Pfizer/BioNTech on Dec 18, 2024; Moderna trial set for Sept 24, 2025.

## SEC filing metadata
- accession: 0001171843-25-000193
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184325000193/0001171843-25-000193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184325000193/f8k_011325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000193
- JSON: https://secwatch.observer/filing/0001171843-25-000193.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.